SCHEMBL3264062

SCHEMBL3264062

CCN(C(=O)CCN)N(CC)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
ADH1C P00326 2/20 0.36
ADH1A P07327 2/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
ALDH1A1 P00352 4/20 0.33
PKM P14618 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 1/20 0.32
MITF O75030 1/20 0.32
RAB9A P51151 1/20 0.32
PAX8 Q06710 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3263172 0.89 L3MBTL1 (0.39) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL3264201 0.86 L3MBTL1 (0.36) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL3260556 0.84 L3MBTL1 (0.41) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL3264991 0.81 ADH1A (0.39) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL3261322 0.80 L3MBTL1 (0.39) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL25982230 0.78 L3MBTL1 (0.63) L3MBTL1SLC6A2SLC6A4KMT2AMEN1
SCHEMBL3259601 0.75 ADH1A (0.39) L3MBTL1ADH1CADH1ASLC6A2SLC6A4
SCHEMBL3259083 0.75 ADH1A (0.37) L3MBTL1ADH1CADH1AALDH1A1NPSR1
SCHEMBL3364038 0.74 ALDH1A1 (0.53) L3MBTL1KMT2AMEN1ALDH1A1PKM
SCHEMBL3261786 0.74 ALDH1A1 (0.32) L3MBTL1KMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 L3MBTL1 874/4885ADH1C 4205/4885ADH1A 3336/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 L3MBTL1 1100/4885ADH1C 4198/4885ADH1A 3701/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 L3MBTL1 999/4885ADH1C 3863/4885ADH1A 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.